Abbott's MDx Sales Rise 11 Percent in Q4 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today reported that its fourth-quarter molecular diagnostics sales rose around 11 percent year over year to $126 million from $114 million in Q4 2010.

The Abbot Park, Ill.-based diagnostics and pharmaceuticals giant reported total sales of $10.38 billion for the quarter, up 4 percent from $9.97 billion. Its net earnings for the quarter were $1.62 billion, or $1.02 per share, up from $1.44 billion, or $.92 per share, for the fourth quarter of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.